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http://dx.doi.org/10.1016/j.stemcr.2016.09.002SUMMARYThe development of human erythroid cells has beenmostly examined inmodels of adult hematopoiesis, while their early derivation dur-
ing embryonic and fetal stages is largely unknown. We observed the development and maturation of erythroblasts derived from human
pluripotent stem cells (hPSCs) by an efficient co-culture system. These hPSC-derived early erythroblasts initially showed definitive char-
acteristics with a glycophorin A+ (GPA+) CD34lowCD36 phenotype and were distinct from adult CD34+ cell-derived ones. After losing
CD34 expression, early GPA+CD36 erythroblasts matured into GPA+CD36low/+ stage as the latter expressed higher levels of b-globin
along with a gradual loss of mesodermal and endothelial properties, and terminally suppressed CD36. We establish a unique in vitro
model to trace the early development of hPSC-derived erythroblasts by serial expression of CD34, GPA, and CD36. Our findingsmay pro-
vide insight into the understanding of human early erythropoiesis and, ultimately, therapeutic potential.INTRODUCTION
Erythroblasts are one of the first blood cells to be gener-
ated during embryonic hematopoiesis (Palis and Yoder,
2001). Investigating the early erythropoiesis is helpful in
comprehending the occurrence and regulation of early
embryonic hematopoiesis. Research in early erythropoi-
esis is largely performed on murine models (Keller et al.,
1999; Palis et al., 1999). The lack of proper in vitro and
in vivo systems hampers the observation of this process
during human embryonic/fetal development. The isola-
tion of human embryonic stem cells (hESCs) (Thomson
et al., 1998) and the establishment of human induced
pluripotent stem cells (hiPSCs) (Takahashi et al., 2007)
have provided excellent tools to investigate early events
in human hematopoiesis. Large-scale production of
hPSC-derived erythroblasts can be achieved in vitro by
mimicking in vivo erythropoiesis (Lu et al., 2008; Ma
et al., 2008). Previously, we found that erythroblasts
were derived from hESC/mouse fetal liver stromal cell
(mFLSC) co-culture and matured continuously (Ma
et al., 2008). In this study, we have modified this method
by co-culturing hPSCs with aorta-gonad-mesonephros
(AGM)-S3 cells (Xu et al., 1998), which were obtained
from the earliest definitive hematopoiesis-supporting
region (Matsuoka et al., 2001), to study human early
erythropoiesis.
The maturation of human erythroblasts from adult
CD34+ hematopoietic stem/progenitor cells (HSPCs) canStem Cell R
This is an open access article under the Cbe assessed by serially tracing the expression of erythroid
lineage markers. These markers for adult-type erythro-
blasts’ developmental process are widely used to recognize
hPSC-derived erythroblasts, along with analysis of their
functional properties. However, there is no detailed
information about how erythroid cells originate from
hPSC-derived progenitors and which phenotypes they
share during the early developmental stages, hindering
the elucidation of step-by-step mechanisms that control
human early erythropoiesis from hPSCs.
Phenotypically, adult-type hematopoietic stem cell
(HSC)-derived erythroblasts mature by losing CD34
and then gaining glycophorin A (GPA; also known as
CD235a) on their surface. CD36 co-expresses with GPA
when cells are committed to erythroid lineage. Expression
of CD36 is then gradually downregulated during the termi-
nal maturation stage on enucleated red blood cells (RBCs)
(Okumura et al., 1992; Neildez-Nguyen et al., 2002; Fajtova
et al., 2013; Li et al., 2014). However, in this study we
demonstrated that the expression process of CD34, GPA,
and CD36 on hPSC/AGM-S3 co-culture-derived early
erythroblasts was distinct. These hPSC-derived early eryth-
roblasts were generated from endothelium precursors, un-
derwentmaturation by losingmesodermal and endothelial
properties, and gradually gained definitive erythropoietic
potential. Our results suggest that a unique pathway for
early definitive erythropoiesis from hPSCs is phenotypi-
cally different from that of adult HSPC-derived definitive
erythropoiesis.eports j Vol. 7 j 869–883 j November 8, 2016 j ª 2016 The Authors. 869
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Generation of Erythroid Cells Derived from hPSC/AGM-S3 Co-culture
(A) Schematic showing the strategy for generation of erythroid cells from hPSCs via co-culture with AGM-S3 cells.
(B) Cells were digested with 0.25% trypsin/EDTA. The figure shows numbers of total cells, HSPCs (CD34+CD45+), hematopoietic cells
(CD45+), and GPA+ cells derived from H1 cells in co-culture over time (independent experiments, n = 3; mean ± SD). There were 13 104 H1
cells initially. The total cell numbers exclude the numbers of AGM-S3 cells in co-culture.
(C) Representative flow cytometry data showing co-expression of CD34/CD45 and GPA/CD71 in day-14 co-culture. CD34 and CD45 are
important hematopoietic markers while GPA and CD71 are markers of erythroid cells.
(legend continued on next page)
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RESULTS
Generation of Erythroblasts from hPSC/AGM-S3 Co-
culture
We have established an efficient culture system to generate
considerable numbers of erythroblasts from hPSCs by co-
culture with AGM-S3 cells (Figure 1A). Hematopoiesis in
hPSC/AGM-S3 co-culture was similar to that in hESC/
mFLSC co-culture, as we reported previously (Ma et al.,
2008). In hPSC/AGM-S3 co-culture the total cell number
gradually increased, peaked at day 14, and decreased there-
after (Figure 1B). Fluorescence-activated cell sorting (FACS)
analysis at various time points revealed that the hemato-
poietic cells had been generated from hESC/AGM-S3 co-
culture. About 7.3 ± 0.58 3 104 CD34+CD45+ cells, 1.5 ±
0.13 3 105 CD45+ cells, and 4.01 ± 0.34 3 105 GPA+ cells
were generated on day 14 from 1 3 104 H1 cells (Figures
1B and 1C). GPA is an accepted surface maker for adult
erythroid cells. We examined further the expression of hu-
man hemoglobin in co-culture over time by immunofluo-
rescence (IF) staining analysis. Human hemoglobin-
expressing cells were firstly observed in day-6 co-cultures.
The number of these cells peaked on day 14 and decreased
thereafter (Figure 1D).
To investigate the efficiency of erythroblasts generated
in co-culture at different time points, we performed a
hematopoietic colony-forming cell assay. Considerable
numbers of erythroid colonies (CFU-E [colony-forming
unit-erythroid], BFU-E [burst-forming unit-erythroid],
and CFU-Mix [CFU mixed]) along with myeloid colonies
(CFU-GM [CFU- granulocyte/macrophage]) were generated
from co-cultured cells. Most erythroid progenitors and
CFU-GM progenitors were detected in co-cultures at days
8–10 and day 14, respectively (Figures 1E and 1F). This is
in accordance with the fact that erythroblasts originate
earlier than other myeloid cells in human ontogenesis
(Palis and Yoder, 2001).
The proliferation of erythroblasts determined by IF stain-
ing analysis was consistent with flow cytometry data (Fig-
ures 1B and 1D). The data also suggested that the co-culture
system cannot support the development of erythroblasts(D) Immunofluorescence (IF) analysis showing human hemoglobin ex
from day 4 to day 18 (independent experiments, n = 3; mean ± SD).
(E) Typical morphology of hematopoietic colonies was presented. Tota
culture. Scale bars, 100 mm.
(F) Total H1/AGM-S3 co-cultured cells from day 8 to day 14 were recult
H1 cells initially (independent experiments, n = 3; mean ± SD). Tota
colonies.
(G) Proliferation of GPA+ cells in suspension culture. There were 13 1
resuspended in RBC differentiation medium for further expansion an
mean ± SD).
See also Figure S1.continuously. For further expansion and maturation of
erythroblasts, co-cultures at days 10–12 were resuspended
in optimized erythroblast differentiation medium. After
24 days of suspension culture, initial 1 3 104 H1 cells
yielded more than 3 3 106 GPA+ erythroblasts (pu-
rity >95%) (Figure 1G). A high percentage of these GPA+
erythroblasts at day 24 in suspension culture expressed
adult-type b-globin (84.9% ± 3.1%), proving that they
were of definitive origin, most of which co-expressed
g-globin (98.5% ± 1.8%) and 3-globin (77.6% ± 5.5%),
showing that they still retained embryonic/fetal erythro-
blast features (Figure S1).
Thus, hPSC/AGM-S3 co-culture system for the efficient
production of hPSC-derived erythroblasts has been estab-
lished, which clearly originated via a definitive pathway
of early hematopoiesis (with a high percentage of cells ex-
pressing b-globin). Notably, except for a low concentration
of vascular endothelial growth factor (VEGF), no additional
factor specifically for erythroid development was added
into co-culture, suggesting that the generation of erythro-
blasts from hPSCs is a natural event in the co-culture.
Thismethod provides a feasible tool withwhich to conduct
subtle investigations of early erythropoiesis from hPSCs.
Expression of CD36 on hPSC-Derived GPA+ Cells
The surface markers of adult HSPC-derived erythroblasts
have beenwell studied (Chen et al., 2009). Our flow cytom-
etry data were consistent with previous reports that as hu-
man CD34+ HSPCs differentiate toward erythroblasts, the
expression of CD34 disappeared exclusively before gaining
expression of erythroid lineage markers such as GPA,
CD71, CD36, and CD47 (Figures 2A and S2A). To elucidate
the expression process of surface markers on hPSC-derived
erythroblasts in detail, we detected erythroid-lineage-
related markers established for adult-type erythroblasts,
including GPA, CD71, CD47, CD81, EPO-R, CD117
(c-Kit), CD45, and CD34 (Figure S2B). Among these, the
expression of CD36 on hESC-derived erythroblasts was
obviously different from that on human cord blood
(hCB)-CD34+ HSPC-derived erythroblasts (Figures 2A and
2B). Throughout the co-culture period, CD36 was onlypression in H1/AGM-S3 co-cultured cells obtained every other day
Scale bars, 50 mm.
l day-12 H1/AGM-S3 co-cultured cells were recultured in semi-solid
ured in semi-solid culture. Numbers of colonies derived from 13 103
l colony numbers include the numbers of all colonies except CFU-E
04 H1 cells initially. Total day-12 H1/AGM-S3 co-cultured cells were
d maturation of erythroid cells (independent experiments, n = 3;
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Figure 2. Expression Process of CD36 on Erythroid Cells of Different Origins
(A–C) Representative flow cytometry profiles showing expression of CD36 on GPA+ cells derived from hCB-CD34+ HSPCs (A), H1/AGM-S3 co-
culture (B), and day-10 + 5 and 10 + 9 suspension cultures (C).
(legend continued on next page)
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expressed at a low level on a small proportion of hPSC-
derived GPA+ cells. In humans, CD36 is a determinant
marker of committed erythroid progenitors that is ex-
pressed continuously on normal immature erythroblasts,
and its expression decreases gradually with their matura-
tion (Okumura et al., 1992). In our study, when the eryth-
roblasts were expanded by replating day-10 co-cultured
cells, the cell number of the GPA+CD36low (abbreviated as
G+36low) cell fraction gradually increased and decreased
again, similar to the CD36 expression process on hCB-
CD34+ HSPC-derived erythroblasts (Figures 2C–2E).
To further investigate the expression of CD36 during
maturation of hPSC-derived erythroblasts, we recultured
day-12 H1/AGM-S3 co-cultured cells were in semi-solid
medium, which favors optimal colony formation (with
the addition of six cytokines). After 14 days, seven BFU-E
colonies (1–53 105 cells per colony)were randomly chosen
and subjected to flow cytometry analysis individually. In
each colony, the majority of GPA+ cells were CD36+
(90.3% ± 8.2%) (Figure S2C). Day-10 co-cultured cells
were replated in suspension culture. The percentage and
absolute number of G+36low/+ cells increased after 5 days
(day 10 + 5) and gradually decreased after an additional
4 days (day 10 + 9) (Figures 2C–2E). These data imply
that early erythroid progenitors derived from hPSC/
AGM-S3 co-culture seldom expressed CD36. However, the
CD36 expression was upregulated when co-culture-derived
HSPCs developed to a mature stage, and was gradually
downregulated when they matured further, similar to
hCB-CD34+ HSPCs.
With the same efficiency as they were generated from the
H1 cell line, erythroblasts could also be generated from
other hPSC lines by co-culture with AGM-S3 cells (Fig-
ure 2F). CD36 was expressed at an extremely low level on
KhES-3- and 201B7-derived GPA+ cells in co-culture, similar
to its expressiononH1/AGM-S3co-culture-derivederythro-
blasts (Figure 2F). This result clearly demonstrates that low
or negative expression of CD36 on early erythroblasts is a
commonphenomenon in early erythropoiesis fromhPSCs.
H1/AGM-S3 Co-culture-Derived GPA+CD36low
Erythroblasts AreMoreMature than Early GPA+CD36
Erythroblasts
Toclarify thedevelopmentalprocessoferythroblastsdefined
by their expression of GPA and CD36, we conducted further(D) The percentage of CD36low/+ cells among GPA+ cells at day 10, da
independent experiments.
(E) Proliferation of GPA+CD36low (G+36low) and GPA+CD36 (G+36) cel
(independent experiments, n = 3; mean ± SD).
(F) Proliferation of G+36low and G+36 cell fractions in co-culture de
(independent experiments, n = 3; mean ± SD).
See also Figure S2.examinationbycell sorting.Asalreadynoted,humanhemo-
globin-expressing cells were first observed in day-6 co-cul-
ture (Figure 1D). Thus, cells in day-6 co-culture were divided
into four fractions by FACS according to their expression of
GPAandCD36.May-Gru¨nwald-Giemsa (MGG) and IF stain-
ing showed thatmore than 80%ofGPA+CD36 cells (abbre-
viated as G+36 cells) and G+36low cells were erythroblasts
with expression of human hemoglobin, while GPA cells
rarely expressed human hemoglobin (Figure 3A).
The G+36 and G+36low cell fractions at day-10 and
day-14 co-culture were sorted and examined. IF staining
showed that 100% of G+36 and G+36low cells from day-
10 and day-14 co-cultures expressed human hemoglobin,
confirming that they were all erythroblasts (Figures 3B
and 3C). From days 10 to 14, both G+36 and G+36low
erythroblasts exhibited a significant increase in g- and
b-globin expression. Furthermore, the ratios of G+36low
cells expressing g- and b-globins were considerably higher
than those of the G+36 fraction in both day-10 and day-
14 co-culture (Figures 3B–3D). The hemoglobin composi-
tion assay showed that cells underwent further maturation
gradually. Taken together, these data strongly indicated
that hESC-derived erythroblasts matured over time and
that the maturity of GPA+ cells could be associated with
their expression of CD36.
Thus, we speculated that G+36low cells developed from
G+36 cells. To verify this, we separated G+36 cells in day-
10 H1/AGM-S3 co-culture by FACS and replated them in
SF-RBC+7FCs medium (see Experimental Procedures).
6 days later (day 10 + 6), the cell number increased by
8.5 ± 1.8-fold, and almost half of these daughter cells ex-
pressed CD36 (Figure 3E). Furthermore, the sorted G+36+
cells from day 10 + 5 were recultured for a further 4 days
(day 10 + 5+4) and then matured into G+36 cells (Fig-
ure S3A). This provides concrete evidence that hPSC/AGM-
S3 co-culture-derived erythroblasts were initially G+36,
developed into a more mature CD36low/+ stage, and finally
reached a stage at which all cells were an upregulation of
b-globin along with downregulated expression of CD36.
Early GPA+CD36 Erythroblasts Co-express
Endothelial and Early Hematopoiesis-Related Markers
at High Levels
We also detected other endothelial/hematopoietic markers
that defined early hematopoiesis from hPSCs, such asy 10 + 5, and day 10 + 9 cultures. Data are representative of three
l fractions at day 10, 10 + 5, and 10 + 9 derived from 13 104 H1 cells
rived from 1 3 104 H1, KhES-3, and 201B7 cells on different days
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Figure 3. Characteristics of GPA+CD36low and GPA+CD36 Erythroid Cell Fractions Sorted from H1/AGM-S3 Co-culture
(A) (a) Four cell fractions defined by expression of GPA and CD36 were sorted by FACS from day-6 H1/AGM-S3 co-culture. (b–e) IF analysis
showing human hemoglobin expression in each cell fraction (independent experiments, n = 3; mean ± SD). Scale bars, 20 mm. (f–i) MGG
staining showing typical morphology of each cell fraction. Scale bars, 25 mm.
(legend continued on next page)
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Figure 4. Phenotypic Expressions of
Indicated Erythroid Cell Fractions
Defined by GPA and CD36
Flow cytometry analysis showing represen-
tative phenotypic expression of erythro-
blast fractions G+36low/+ and G+36 at day
10 and day 10 + 5 as well as G+ 36 cells at
day 10 + 9 during a single culture.CD31, CD144, CD34, CD43, CD41a, CD45, and CD81, as
reported previously (Nakayama et al., 2000; Vodyanik et al.,
2006). These markers were detected on different erythroid
populations classified according to CD36 expression from
co-cultures of day 10, and suspension cultures of day 10 +
5 and day 10 + 9 (Figure 4). The majority of hPSC-derived
erythroblasts of day-10 co-cultures co-expressed endothe-
lial marker CD31 at a high level (72.9% for G+36 cells
and 59.6% for G+36low cells), more than half of which co-
expressed definitive hematopoiesis markers CD43 and
CD41a. Along with progressive maturation, these erythro-
blasts exhibited downregulation of CD43 and CD41a asso-
ciated with the loss of endothelial markers. These findings
indicate that early hPSC-derived erythroblasts experienced
a unique pathway that was generated from precursors
sharing endothelial differentiation potential.
Gene Expression Profiles of hESC-Derived
Erythroblasts Defined by Expression of CD36 and GPA
To elucidate the developmental pathway of hPSC-derived
early erythroblasts, we further investigated G+36 cells
from day-10 co-cultures, and G+36 and G+36+ cell frac-
tions from day-10 + 5 cultures. MGG and IF staining
showed that all sorted cell fractions were erythroblasts (Fig-(B) (a) G+36low and G+36 cell fractions were sorted by FACS from da
human hemoglobin and 3-, g-, and b-globins in G+36low (b–d) and G+36
Scale bars, 20 mm. (e and i) MGG staining showing typical morpholog
(C) (a) G+36low and G+36 cell fractions were sorted by FACS from da
human hemoglobin and 3-, g-, and b-globins in G+36low (b–d) and G+36
Scale bars, 20 mm.
(D) The percentages of cells co-expressing hemoglobin and 3-, g-, and
n = 3; mean ± SD; **p < 0.01).
(E) Flow cytometry profiles showing the purity of sorted G+36 cells fro
they were recultured in SF-RBC+7FCs medium for an additional 6 day
experiments, n = 3; mean ± SD).ures S3B and S3C). The gene expression level of these
fractions was analyzed by qRT-PCR and compared with
those of hCB-CD34+ HSPC-derived erythroblasts (G+36+)
(Figure S3D). To further analyze the differences in tran-
scriptional profiles among erythroid cell fractions, we per-
formed pairwise comparisons of genes of interest (Figures
5A–5C).
The transcript levels of the typical mesodermal-related
gene T and endothelial-related genes (KDR, FLT1, PECAM1,
TIE2, and CDH5) were higher in early G+36 erythroblasts
at day 10 of co-culture. In hESC-derived erythroblasts,
expression of the genes (GATA3, PU.1, and PROM1) which
were related to the lymphoid development (Wei et al.,
2011; Zhang et al., 2000; Gorgens et al., 2013) obviously
decreased along with their maturation. These data show
that progressive maturation of hESC-derived erythroblasts
is associated with downregulated mesodermal/endothelial
features and reduction of lymphoid/myeloid potentials.
SCL and LMO2 are involved in both primitive and defin-
itive hematopoiesis (Porcher et al., 1996; Warren et al.,
1994), and RUNX1 is a key hematopoietic transcription fac-
tor required for definitive hematopoiesis (Okuda et al.,
1996). SCL and LMO2 expression levels in H1/AGM-S3
co-culture-derived erythroblasts were comparable withy-10 H1/AGM-S3 co-culture. IF analysis showing co-expression of
 (f–h) cell fractions (independent experiments, n = 3; mean ± SD).
y of G+36low and G+36 cell fractions. Scale bars, 10 mm.
y-14 H1/AGM-S3 co-culture. IF analysis showing co-expression of
 (e–g) cell fractions (independent experiments, n = 3; mean ± SD).
b-globins among erythroid cell fractions (independent experiments,
m day-10 H1/AGM-S3 and expression of CD36 on their progeny after
s. The total number of cells expanded 8.5 ± 1.8-fold (independent
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Figure 5. Heatmaps and PCA for qRT-PCR
Results of hESC-Derived Erythroid Cell
Fractions Defined by Expression of GPA
and CD36
(A–C) Pairwise comparison of transcription
levels for selected genes in the erythroid
cell fractions. Heatmaps of selected genes
associated with mesodermal, endothelial,
hematopoietic, and erythroid cells. In each
row, red, black, and green reflect high,
medium, and low expression of the given
gene, respectively (independent experi-
ments, n = 3).
(D) PCA plots of three biological replicates
of the five erythroid cell fractions.
See also Figure S3.those in hCB-CD34+ HSPC-derived erythroblasts, while
RUNX1 expression was higher in hESC-derived erythro-
blasts. These data suggest that hESC-derived erythro-
blasts in our system have a tendency to form definitive
hematopoiesis.
GATA switch is a key regulation pathway for erythropoi-
esis in mice (Suzuki et al., 2003; Tsai and Orkin, 1997) and
also from human adult-type HSPCs (Li et al., 2014). GATA1
expression was higher than GATA2 in hESC-derived eryth-
roblasts. During maturation, GATA1 expression in hPSC-876 Stem Cell Reports j Vol. 7 j 869–883 j November 8, 2016derived G+36 cells from day-10 + 5 suspension culture
was higher than that from day-10 co-culture, then
decreased when cells reached the G+36+ stage at day 10 +
5 of suspension culture. Expression of GATA2was opposite
to that of GATA1. Our findings demonstrate that decisive
switching of GATA factors also occurs during the early
erythropoiesis from hESCs.
hESC-derived erythroblasts expressed higher levels of em-
bryonic and fetal ( 3- andg-) globins and lower levels of adult-
type (d- and b-) globins than hCB-CD34+ HSPC-derived
erythroblasts. Meanwhile, HBB expression gradually
increased following the progressive maturation of hESC-
derived erythroblasts. Similar to previous reports, we found
increases in IKAROS and EKLF expression and a decrease
in MYB expression, which confirmed that the g-/b-globin
switch occurred in erythropoiesis from hESC (Bottardi
et al., 2009; Dijon et al., 2008; Jiang et al., 2006).
In principal component analysis (PCA) (Figure 5D), three
biological replicates of different erythroid cell fractions
were tightly clustered, demonstrating that the cell fractions
provided reproducible transcription profiles. G+36+ eryth-
roblasts derived from hCB-CD34+ HSPCs were separated
from all hESC-derived erythroid cell fractions according
to PC1, which was primarily associated with differences
in expression of HBE, KDR, and KIT. hESC-derived erythro-
blasts expressed relatively high levels ofHBE andKDR and a
low level of KIT, suggesting that they had mesodermal and
embryonic properties during their development and were
less reliant on stem cell factor (SCF) than hCB-CD34+
HSPC-derived erythroblasts. hESC-derived erythroblasts
were clearly separated according to PC2, which was mainly
associated with downregulation of TIE2, GATA3, and KDR.
In complete agreement with our previous results, hESC-
derived erythroblasts lost their mesodermal/endothelial
features and lymphoid/myeloid potentials continuously
during their progressive maturation.
GPA+CD34low Cells Define a Unique Pathway for Early
Development of Definitive Erythroblasts
From flow cytometry data and gene expression profiles,
hESC-derived G+36 erythroblasts at day 10 have obvi-
ously mesodermal and endothelial features. To explore
their precursors, we tracked the expression of mesodermal
and endothelial surface markers on GPA+ cells in early
H1/AGM-S3 co-culture. We found that there exists a tran-
sient specific cell fraction GPA+CD34low (abbreviated as
G+34low), which was generated from early H1/AGM-S3
co-culture by day5, burst out on day 7, peaked on day 10,
and then disappeared gradually (Figure 6A).
Expression of surface markers including endothelial,
hematopoietic, and erythroid lineage was investigated
on G+34low and G+34 cells at day 7 of co-culture. The
G+34low cells expressed a high level of endothelial marker
CD31 and a low level of definitive hematopoietic markers
(CD43 and CD41a). They also expressed a low level of
CD71 and little CD36, both serving as erythroid lineage
markers (Figure S4A). Fewer than 10% of day-7 G+34low
cells expressed human hemoglobin (data not shown),
while adult-type b-globin was detectable in both G+34low
and G+34 cells in day-7 co-culture, with a positive ratio
of 1.7%± 0.2%and13.8%±1.4%, respectively (Figure S4B).
These data showed that the G+34low cells in day-7 co-cul-
ture were composed of a majority of endothelium and asmall portion of definitive erythroblasts, while loss of
expression of CD34 on GPA+ cells led to further erythroid
maturation.
We further analyzed the properties of GPA+CD34low/
cell fraction in day-10 co-culture. Compared with
G+34low/ cells at day 7, they expressed a lower level of
CD31 but higher CD144. The expression levels of CD43,
CD41a, and CD71 also increased remarkably (Figure S4A).
We found that 62.4% ± 3.7% of G+34low cells in day-10
co-culture expressed human hemoglobin, showing their
erythroid features, while lost CD34 expression gave rise
to almost solely erythroid cells (97.7% ± 0.3% of G+34
cells expressing human hemoglobin) (Figure 6B).
For the detection of differentiation potential, four cell
fractions defined by expression of GPA and CD34 were
sorted from day-10 H1/AGM-S3 co-culture and recultured
in medium, fully supporting myeloid cell differentiation.
After 8 days, daughter cell numbers of G+34low, G+34,
and G34+ cell fractions expanded 2.38 ± 0.48-, 1.75 ±
0.5-, and 1 ± 0.41-fold, respectively. While G34 cells
were not maintained in the culture (Figure 6C), most of
the daughter cells from sorted G+34low and G+34 cells
were erythroid cells expressing adult-type b-globin (Fig-
ure 6D) and few other myeloid cells were found. 2.15 ±
0.71 3 104 and 1.55 ± 0.44 3 104 hemoglobin+ cells were
generated from 1 3 104 original G+34low and G+34 cells,
respectively. Obviously the proliferation potential of
G+34low cells was higher than that of G+34 cells, and
both terminally gave rise to b-globin+ erythroblasts. On
the other hand, daughter cells from G34+ cells generated
myeloid progenitors, mast cells, and macrophages but
never erythroid cells (Figure S4C).DISCUSSION
Human early erythropoiesis has been primarily studied
using adultmodels with definitive hematopoiesis. Through
subtle investigations, several laboratories reported that
the regulatory pathway of definitive erythropoiesis devel-
opment from adult HSPCs can be serially tracked by the
expression of erythroid lineage surface markers, particu-
larly CD34, GPA, CD71, and CD36 (Freyssinier et al.,
1999; Gregory and Eaves, 1978). However, this may not
be applicable to definitive erythropoiesis of hPSCs (Giarra-
tana et al., 2011; Lu et al., 2008). In the present study, we
investigated hPSC-derived early definitive erythroblasts
during their development defined by expression of GPA,
CD34, and CD36 (Figure 7). A unique cell population of
GPA+CD34lowCD36 is firstly generated by day 5 of H1/
AGM-S3 co-culture. Then, by losing CD34 expression,
they developed and matured sequentially to G+3436,
G+3436low/+ and then G+3436 erythroblasts with aStem Cell Reports j Vol. 7 j 869–883 j November 8, 2016 877
Figure 6. Characteristics of GPA+CD34low
and GPA+CD34 Cell Fractions in H1/
AGM-S3 Co-culture
(A) Representative flow cytometry data
showing co-expression of CD34 and GPA on
co-cultured cells over time. The co-cultured
cells were digested by 0.1% trypsin/EDTA.
(B) G+34low and G+34 cell fractions in day-
10 H1/AGM-S3 co-culture. (a) Cell fractions
defined by expression of GPA and CD34 were
sorted by FACS from day-10 H1/AGM-S3 co-
culture. (b and c) IF analysis showing co-
expression of human hemoglobin in G+34low
and G+34 cell fractions (independent ex-
periments, n = 3; mean ± SD). Scale bars,
20 mm. (d and e) MGG staining showing
represent morphology of G+34low and G+34
cell fractions, respectively. Scale bars,
10 mm.
(C) Cell fractions defined by GPA and CD34
were sorted from day-10 H1/AGM-S3 co-
culture and recultured in myeloid cells
supporting medium. Original 1 3 104 cells
were replated in one 24-plate well. After
8 days, hemoglobin+ and hemoglobin cell
numbers derived from G+34low, G+34,
G34+, and G34 cell fractions were pre-
sented, respectively (independent experi-
ments, n = 3; mean ± SD).
(D) Daughter cells of G+34low and G+34
cells sorted from day-10 H1/AGM-S3 co-
culture. (a and b) IF analysis showing
expression of human hemoglobin in the
daughter cells (independent experiments,
n = 3; mean ± SD). Scale bars, 20 mm. (c and d) IF analysis showing co-expression of human hemoglobin and b-globin in the daughter cells
(independent experiments, n = 3; mean ± SD). Scale bars, 10 mm. (e and f) MGG staining showing typical morphology of the daughter cells.
Scale bars, 10 mm.
See also Figure S4.gradual upregulation of b-globin. It is reported that
before CD34+cells occur, GPA is firstly expressed on
KDR+CD34CD144 (abbreviated as G+K+34144) meso-
dermal cells (Sturgeon et al., 2014; Vodyanik et al., 2006),
which could generate exclusively primitive hematopoiesis.
However, the GPA+CD34low36 cells generated in H1/
AGM-S3 co-culture are different from those early meso-
dermal cells. Since CD34 is known as an important marker
of endothelial/hematopoietic cells, according to our data
GPA+CD34low36 cells in day-7 co-culture are endowed
with endothelial features while a small portion of them
have already shared definitive erythroid potential. More
than one-quarter of them express CD71 and even 1.7% ±
0.2% have already expressed adult-type b-globin. Conse-
quently, the GPA+CD34low36 (G+34low36) cells in day-
10 co-culture showed an enhanced generation of erythro-
blasts (hemoglobin-positive cells >60%). When purified878 Stem Cell Reports j Vol. 7 j 869–883 j November 8, 2016by cell sorting, these day-10 co-culture-derived GPA+
CD34low cells can further proliferate and generate defini-
tive erythroblasts with very high levels of b-globin
(>95%), proving their definitive erythroid potential.
Accumulated data in our laboratory suggest that, by co-
culture with AGM-S3, the hPSC-derived early erythroblasts
may originate from definitive endothelium precursors that
differ from adult-type HSC-derived erythroblasts. Human
adult-type HSPCs enriched in hCB or peripheral blood
(hPB) are phenotypically CD34+CD45+, while committed
erythroid cells expressing GPA appear only after CD34
disappears. There is no co-expression of GPA and CD34
stage throughout the developmental process of adult-
type HSC-derived erythroblasts. Clearly, the G+34low36
early precursors derived from our H1/AGM-S3 co-culture
are CD45 negative, showing their lack of HSPC or myeloid
source.
Figure 7. Model of Early Definitive Eryth-
roblasts Derived from hPSCs Defined by
Expression of CD34, GPA, and CD36
There is a specific development stage during
erythropoiesis from hPSCs/AGM-S3 co-
culture. Early definitive erythroblasts are
derived from G+34low36, which occurred
by day 6. They develop to G+3436,
G+3436low/+, and G+3436 cells in
sequence. During G+3436low/+ cells mature
into G+3436 cells, flow cytometry
data and gene expression profiles show
hPSC-derived early definitive erythroblasts
mature in association with decreases in
endothelial and lymphoid potentials.The Douay group reported that when adult HSC-derived
mature erythroblasts were peripherally injected into the
donor, at least half could survive in circulation for as
long as 26 days (Giarratana et al., 2011). However, these
in vitro expandedmature erythroblasts did not accumulate
in a specific organ when injected into NOD/SCID mice
(Neildez-Nguyen et al., 2002), suggesting that they are
not a suitable long-term transplantable cell source
for curing erythroblast deficiencies in patients. hPSC-
derived early G+34low36 cells highly co-expressed endo-
thelial markers and generated more erythroblasts than
G+3436 cells. These G+34low36 cells may be more effi-
cient in homing to the hematopoietic niche and thus in
helping to cure disorders with early erythropoiesis. Some
practical mouse models have been established to trackand qualify human erythroblasts in vivo (Getman et al.,
2014; Ghinassi et al., 2011; Hu et al., 2011). In future, we
will transplant hPSC-derived early G+34low36 cells into
immunodeficient mice on a large scale to study their
behavior in vivo.
Upon precise sorting and reculture, hPSC-derived early
immature G+3436 erythroblasts in our co-culture system
intrinsically developed into a more mature G+3436low
stage with a high proliferation potential. This demon-
strates that the early development and maturation of
hPSC-derived erythroblasts can be traced by the co-expres-
sion of GPA and CD36. Similar to the maturation pathway
of hCB-CD34+ HSPC-derived erythroblasts, expression of
CD36 on hPSC-derived erythroblasts was downregulated
at the terminal differentiation stage. Our observationsStem Cell Reports j Vol. 7 j 869–883 j November 8, 2016 879
provide evidence of a poorly characterized early erythroid
developmental stage during hPSC differentiation, typically
characterized as G+3436 cells.
CD36 is an integral transmembrane protein with a high
affinity for a variety of antibodies. CD36 gene deficiency
is much more prevalent in Asian populations than in Cau-
casians (0%–0.3%) (Tanaka et al., 2001). This deficiency
causes platelet refractoriness, post-transfusion thrombocy-
topenic purpura, neonatal alloimmune thrombocyto-
penia, and other disorders (Hirano et al., 2003; Neculai
et al., 2013; Rac et al., 2007). However, deficiency of
CD36 has no effect on development of erythroblasts
(Toba et al., 2001). CD36, in our present study, is only an
effective co-marker for tracing the developing erythroid
lineage cells, a method that has been widely used (Wong
et al., 2010; Okumura et al., 1992).
The finding that early erythroblasts derived from hPSC/
AGM-S3 (H1, KhES-3, and 201B7) were G+36 suggests
that a CD36 stage is common in early erythropoiesis
from hPSCs. hPSC-derived erythroblasts generated from
erythroid bodies (EBs) in vitro seldom express CD36 (Giar-
ratana et al., 2011; Lu et al., 2008). It is unclear whether
these hPSC-derived CD36 erythroblasts share immature
properties with early erythroblasts in our system or have
undergone terminal maturation into a CD36 stage.
Similar to hCB-CD34+ HSPC-derived erythroblasts, BFU-
Es derived from day-12 co-culture mostly gave rise to
CD36+ daughter cells in suspension culture and reached
100% expression of b-globin (data not shown). These find-
ings demonstrate that our co-culture method favors pro-
gression to definitive hematopoiesis. On the other hand,
EB-derived hematopoietic progenitors do not directly
develop to the mature stage. Whether hPSC-derived he-
matopoietic cells follow a definitive pathway largely de-
pends on their culture environment. The system of EBs
co-culture with OP9 is widely used to generate definitive
hematopoietic cells from hPSCs. However, because of
the unnatural property of OP9 and the artificially
sectioned culture steps, this model is not appropriate
for the study of the natural progression of human
erythropoiesis.
In the current co-culture system, undifferentiated hPSCs
are cultured with definitive hematopoietic niche-derived
AGM-S3 cells. Thus, this approach provides a unique and
ideal tool for the analysis of the serial progression and
maturation of hPSC-derived erythroblasts. This enables us
to further elucidate the mechanisms underlying diseases
with early erythropoiesis, particularly by establishing iPSCs
from patients such as those with Diamond-Blackfan ane-
mia (Vlachos et al., 2014). Many efforts have also been
made for the efficient large-scale manufacture of hPSC-
derived erythrocytes (Slukvin, 2010; Olivier et al., 2012; Pe-
rugini et al., 2009; Smith et al., 2013; Kurita et al., 2013).880 Stem Cell Reports j Vol. 7 j 869–883 j November 8, 2016Meanwhile, practical solutions for enucleation (Fujimi
et al., 2008) and hemoglobin switching (Xu et al., 2012)
of erythrocytes developed from hPSCs are required. Our
co-culture system developed here may benefit the breaking
down of these barriers to generatingmature erythrocytes in
future clinical applications.EXPERIMENTAL PROCEDURES
Maintenance of hPSC Lines
Two hESC lines (H1 and KhES-3) and one hiPSC line (201B7) were
used in this study. All hPSC lines were maintained in an undiffer-
entiated state and passagedweekly on irradiatedmouse embryonic
fibroblasts as described previously (Thomson et al., 1998). The
study was approved by the Institutional Ethic Committee of
the Institute of Blood Transfusion, Chinese Academy of Medical
Sciences & Peking Union Medical College.
Differentiation of hPSCs into Erythroblasts
Approximately 1–2 3 104 undifferentiated hPSCs were seeded
together with 2–3 3 105 irradiated AGM-S3 cells in each well of a
6-well plate and cultured in hPSC maintenance medium. Three
days later, the medium was replaced by Iscove’s modified Dulbec-
co’s medium (IMDM) +10% fetal bovine serum (FBS) (Hyclone),
1% non-essential amino acids, 50 mg/mL ascorbic acid, and
20 ng/mL VEGF, representing day 0 of differentiation. Co-culture
at days 10–12 was harvested and transferred to an ultra-low attach-
ment plate with serum-free expansion medium supplemented
with 100 ng/mL SCF, 100 ng/mL interleukin-6 (IL-6), 5 ng/mL
IL-3, 10 ng/mL fetal liver, 10 ng/mL thrombopoietin (TPO), 4 IU/
mL erythropoietin (EPO), and 20 ng/mL VEGF for 6 days (named
SF-RBC+7FCs). Thereafter, cells were cultured as described previ-
ously (Giarratana et al., 2005). Cultures were referred to days of
co-culture plus days of suspension culture.
Erythroblasts Derived fromHumanCord Blood CD34+
HSPCs
To generate adult-type erythroblasts, we isolated hCB-CD34+
HSPCs using CD34+ Dynabeads (Invitrogen; purity >95%) and
cultured them in serum-free medium as described previously
(Giarratana et al., 2005).
Sorted Cells Recultured in Myeloid Supporting
Medium
Cell fractions defined by GPA and CD34 were sorted from day-10
H1/AGM-S3 and were recultured in IMDM added with 20% FBS
(Hyclone), containing cytokines cocktails (100 ng/mL SCF,
10 ng/mL IL-3, 50 ng/mL IL-6, 10 ng/mL Flt3 ligand, 8 IU/mL
EPO, 10 ng/mL granulocyte colony-stimulating factor, and
10 ng/mL TPO).
Hematopoietic Colony Assay
CFU-E, BFU-E, CFU-Mix, and CFU-GM progenitors in H1/AGM-S3
co-culture were characterized as previously described (Ma et al.,
2008).
Flow Cytometric Analysis and Cell Sorting
In briefly, the aforementioned cells were prepared as previously
described (Ma et al., 2008). The antibodies used are presented in
Table S1. Cells were then acquired using a flow cytometer (BD
FACS Canto II) or sorted using a FACS Cytometer System (MoFlo
Astrios, Beckman Coulter). Data were analyzed using FlowJo soft-
ware (Version 7.6.5).
hCB-CD34+ HSPC-derived erythroblasts strongly expressed
CD36, as determined by staining with a fluorescein isothiocyanate
(FITC)-conjugated anti-CD36 antibody. On H1/AGM-S3-derived
GPA+ cells in co-culture, CD36 was almost undetectable with an
FITC-conjugated anti-CD36 antibody but detectable with an
APC-conjugated anti-CD36 antibody (data not shown). Hence,
the APC-conjugated anti-CD36 antibodywas used to subsequently
examine hPSC-derived erythroblasts.
Morphological Observation and Immunofluorescence
Staining Analysis
Harvested cells were centrifuged onto glass slides using a Cell
Cytospin machine (Cytospin 4, Thermo Fisher Scientific). For
morphological observation, MGG staining was performed. The
hemoglobin composition of erythroblasts was examined by IF
staining analysis as described previously (Ma et al., 2008). The
antibodies used are presented in Table S2.
qRT-PCR Analysis
The gene expression profiles of the various erythroblast fractions
were analyzed by qRT-PCR. Total RNA was extracted from cells us-
ing the PureLink RNA Micro Kit (Invitrogen). cDNA was synthe-
sized using the iScript cDNA Synthesis Kit (Bio-Rad). The primers
used are listed in Table S3. The reactions were performed in a ther-
mal cycler (iQ5, Bio-Rad). Gene expression levels were calculated
using the minimal cycle threshold (Ct) values normalized to the
expression of the housekeeping gene GAPDH in each sample. All
reactions were performed in triplicate.
Heatmaps and Principal Component Analysis
qRT-PCR data were analyzed to generate heatmaps. Cluster anal-
ysis was performed using Cluster and visualized using Java Tree-
view. PCA was performed using Cluster and visualized using R
package (ggplot2).
Statistical Analysis
ThemeanandSEof three independentexperimentswerecalculated.
Data are shown as themean ± SD. Statistical significance was evalu-
ated using the Student’s t test. p < 0.05 was considered significant.
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